Global Migraine Market, By Types (Episodic, Chronic), Symptoms (Food Cravings, Depression, Fatigue, Frequent Yawning, Hyperactivity, Irritability, Neck Stiffness, Others), Treatment (Medication, Acupressure, Counseling, Hormone Therapy, Others), Diagnosis (Computerized Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.
Global Migraine Market Analysis and Size
In recent years, the migraine market is anticipated to grow rapidly during the forecast period. Migraine is the world's 19th most prevalent cause of disability, according to the World Health Organization. Migraine sufferers take twice as many prescription drugs and visit doctors and emergency rooms twice as often as individuals who do not suffer from the condition. Migraine sufferers have also spent significantly more on healthcare. Migraine sufferers are observed to consume 2.5 times as many prescription drugs and have six times the number of diagnostic tests and services as non-migraine sufferers. As a result of the rising occurrence of migraine, more therapies are being used to provide relief, which serves to drive the entire market.
- Data Bridge Market Research analyses that the migraine market was valued at USD 3.5 billion in 2021 and is expected to reach USD 4.83 billion by 2029, registering a CAGR of 4.10% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Global Migraine Market Definition
Migraine is a neurological illness that causes throbbing pain in the forehead, side of the head, or around the eyes in one person only. Autonomic symptoms such as nausea, vomiting, photophobia, and phonophobia are frequently associated with the pain. Migraine is usually diagnosed by looking at the patient's medical history and symptoms, as well as performing blood tests and MRI and CT scans. To ease the symptoms and lessen the frequency and intensity of migraine attacks, over-the-counter (OTC) medications and prescription injections are currently available. These medications are taken either on a regular basis or in response to attacks or exacerbations of chronic pain.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Types (Episodic, Chronic), Symptoms (Food Cravings, Depression, Fatigue, Frequent Yawning, Hyperactivity, Irritability, Neck Stiffness, Others), Treatment (Medication, Acupressure, Counseling, Hormone Therapy, Others), Diagnosis (Computerized Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (US), Merck & Co., Inc. (US), Allergan (Ireland), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Cipla Inc. (US), Amneal Pharmaceuticals LLC. (US), Eisai Co., Ltd. (Japan), Bausch Health Companies Inc. (Canada), Abbott (US), Takeda Pharmaceutical Company Limited (Japan), WOCKHARDT (Mumbai), AbbVie Inc. (US), Merck KGaA (Germany)
|
|
Market Opportunities
|
|
Migraine Market Dynamics
Drivers
-
Increasing Prevalence of Migraine
The rising prevalence of migraine is a primary driver of the migraine market's growth. Growing addiction of smoking and increasing alcohol consumption are the major factors that will enhance the prevalence of migraine and influencing the market dynamics during the forecast period.
-
Rising Demand for Precision Medicines
Growing demand for precision medicines will enhance the growth rate of market. Along with this, the improvement in reimbursement policies for migraine medications will propel the market’s growth rate.
-
Increasing Investment for Healthcare Infrastructure
Another significant factor influencing the growth rate of migraine market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the migraine market. Additionally, high disposable income and increasing demand for nerve stimulation devices to treat migraine will result in the expansion of migraine market. Along with this, rising geriatric population and the advent of calcitonin gene-related peptide (CGRP) monoclonal antibodies will enhance the growth rate of the market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the migraine market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the migraine market growth during the forecast period.
Restraints/Challenges Global Migraine Market
On the other hand, the high cost associated with the treatment of migraine will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the migraine market. Additionally, a decline in clinical visits due to COVID0-19 outbreak and procedural treatment of migraines due to social distancing norms will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This migraine market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the migraine market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Migraine market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Migraine Market
Several worldwide markets have been harmed by the global coronavirus pandemic. COVID-19 cases and patient care were keeping the health sector busy. During this time, the pharmaceutical and drug research industries were experiencing a surge in demand. The migraine market, on the other hand, is being impacted by the virus outbreak. Various medications for the treatment of COVID-19 were being tested by the pharmaceutical industry. In addition, migraine drug testing for COVID-19 were having a beneficial impact on the market.
During this time, there is a lot of dirge research going on. The majority of biopharmaceutical businesses use this time to create new medications. The migraine medicine industry is keeping track of drug compositions and effects. Demand will rise as a result of the considerable research into the migraine sector. In addition, in the coming years, a wider choice of medications and treatments will be available. All of these will assist the migraine market as a whole.
Recent Development
- In September 2021, FDA had approves the first and only oral CGRP receptor antagonist named QULIPTA™ (atogepant), which is specifically developed for the preventive treatment of migraine. CGRP and its receptors are used for nervous system associated with migraine pathogenesis, and CGRP levels have been found to be higher during migraine attacks in studies. QULIPTA is a once-daily medication that blocks CGRP. It comes in three different strengths including 10 mg, 30 mg, and 60 mg.
Global Migraine Market Scope
The migraine market is segmented on the basis of type, symptoms, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Types
- Episodic
- Chronic
On the basis of type, the migraine market is segmented into episodic, and chronic.
Symptoms
- Food Cravings
- Depression
- Fatigue
- Frequent Yawning
- Hyperactivity
- Irritability
- Neck Stiffness
- Others
On the basis of symptoms, the migraine market is segmented into food cravings, depression, fatigue, frequent yawning, hyperactivity, irritability, neck stiffness, and others.
Treatment
- Medication
- Acupressure
- Counseling
- Hormone Therapy
- Others
On the basis of treatment, the global migraine market is segmented into medication, acupressure, counseling, hormone therapy and others. Medication segment is further segmented into pain-relieving medications, and preventive medications. Pain-relieving medications are further sub-segmented into anti-nausea drugs, opioid medications, CGRP antagonists, ubrogepant, lasmiditan, dihydroergotamine, triptans, and pain relievers. Preventive medications are further sub-segmented into CGRP monoclonal antibodies, botox injections, anti-seizure drugs, antidepressants, and blood pressure-lowering medications.
Diagnosis
- Computerized Tomography (CT) Scan
- Magnetic Resonance Imaging (MRI)
- Others
On the basis of diagnosis, the migraine market is segmented into computerized tomography (CT) scan, magnetic resonance imaging (MRI), and others.
Route of Administration
- Oral
- Parenteral
- Others
The route of administration segment for the migraine market is segmented into oral, parenteral and others.
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
On the basis of end-users, the migraine market is segmented into hospitals, specialty clinics, homecare and others.
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
On the basis of distribution channel, the migraine market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.
Migraine Market Regional Analysis/Insights
The Migraine market is analysed and market size insights and trends are provided by country, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Migraine market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the migraine market because of the growing prevalence of migraine in this region. Additionally, growing focus of major key players on novel technology will further propel the market’s growth rate in this region.
Asia-Pacific are expected to grow during the forecast period of 2022 to 2029 due to rise in the number of population and rising healthcare expenditure in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Migraine Market Share Analysis
The Migraine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to migraine market.
Some of the major players operating in the migraine market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd.(Jerusalem)
- Sanofi (France)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (US)
- Merck & Co., Inc. (US)
- Allergan (Ireland)
- AstraZeneca (UK)
- AbbVie Inc. (US)
- WOCKHARDT (Mumbai)
- Johnson & Johnson Private Limited (US)
- Cipla Inc. (US)
- Amneal Pharmaceuticals LLC. (US)
- Eisai Co., Ltd. (Japan)
- Bausch Health Companies Inc. (Canada)
- Abbott (US)
- Takeda Pharmaceutical Company Limited (Japan)
- Merck KGaA (Germany)
SKU-